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ABSTRACT
Aim: to evaluate the comparison of palliative treatment using esophageal stenting alone or in combination 
with radiotherapy.
Method: 3DWLHQWSUREOHPLQWHUYHQWLRQFRPSDULVRQDQGRXWFRPH3,&2V\VWHPZHUHXVHG:HFRQGXFW
a searching in PubMed site. The next process was selection by reading all articles (10 articles). There were 9 
DUWLFOHVH[FOXGHGIURPDQDO\VLV:H¿QDOO\FKRRVHRQHUDQGRPL]HGWULDOVWXG\ZULWWHQE\-DYHG$3DO6'DVK
NR, Ahuja V, Mohanti BK, Vishnubhatla S, et al goes to the critical appraisal step.
Results: The result of this study showed that d\VSKDJLDVFRUHV LPSURYHGVLJQL¿FDQWO\ LQ both groups, in 
patients with inoperable esophageal cancer treated with esophageal stenting alone (group I) and a combination 
of esophageal stenting and radiotherapy (group II) following stent insertion. However, dysphagia relief was 
more sustained in group II than in group I (7 vs. 3 months, p = 0.002). 
Conclusion: In this evidence-based case report (EBCR), we reported a man who suffered from dysphagia 
caused by inoperable esophageal carcinoma. Based on the critical appraisal of the randomized trial collected 
SUHYLRXVO\ IURP3XE0HGZLWK VSHFL¿F FULWHULDVZH FRQFOXGH WKDW D FRPELQDWLRQ RI HVRSKDJHDO VWHQW DQG
radiotherapy effectively prolongs duration of dysphagia relief and improves the overall survival, without 
increasing the incidence of complications.
Keywords: palliative stenting, radiotherapy, inoperable esophageal cancer
ABSTRAK
Tujuan: Untuk mengevaluasi perbandingan pengobatan paliatif menggunakan stenting saja atau 
dikombinasikan dengan radioterapi.
Metode: 6LVWHPSDWLHQWSUREOHP LQWHUYHQWLRQ FRPSDULVRQ DQGRXWFRPH 3,&2GLJXQDNDQ'LODNXNDQ
pencarian di situs PubMed. Proses berikutnya adalah memilih dan membaca seluruh artikel (10 artikel). Ada 9 
artikel yang dikeluarkan dari analisis. Akhirnya dipilih salah satu penelitian percobaan acak yang ditulis oleh 
Javed A, Pal S, Dash NR, Ahuja V, Mohanty BK, Vishnubhatla S, et al dan lanjut pada langkah penilaian kritis.
Hasil: 3HQHOLWLDQLQLPHQXQMXNNDQEDKZDVNRUGLVIDJLDPHQLQJNDWVHFDUDVLJQL¿NDQSDGDNHGXDNHORPSRN
yaitu pada pasien kanker esofagus yang dioperasi dan cukup diobati dengan esofagus stenting saja (kelompok 
I) dan pasien kanker esofagus yang dioperasi dan diobati dengan kombinasi stenting esofagus dan radioterapi 
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(kelompok II) berikut pemasangan stent. Namun, pemulihan disfagia lebih baik pada grup II daripada grup I 
(7 vs. 3 bulan, p = 0,002).
Simpulan: Dalam laporan kasus berbasis bukti ini, dilaporkan seorang pria yang menderita disfagia 
disebabkan oleh kanker esofagus yang tidak bisa diatasi dengan operasi. Berdasarkan penilaian kritis dari uji 
coba acak yang dikumpulkan dari PubMed dengan kriteria tertentu, disimpulkan bahwa kombinasi stenting 
esofagus dan radioterapi efektif memperpanjang durasi pemulihan disfagia dan meningkatkan kelangsungan 
hidup secara keseluruhan, tanpa meningkatkan kejadian komplikasi.
Kata kunci: stenting paliatif, radioterapi, kanker esofagus inoperable
INTRODUCTION
Esophageal cancer is an aggressive gastrointestinal 
malignancy with a poor prognosis.1 It is diagnosed in 
about 400,000 patients each year worldwide, and its 
incidence is increasing.2 Due to the lack of widespread 
screening methods, its insidious symptomatology, 
a late clinical presentation, and rapid progression, 
diagnosis is usually made at advanced stages.1,3 
Therefore the 5-year survival rate of patients with 
esophageal cancer is less than 20%. Most patients 
already present with locally advanced, unresectable 
or metastatic disease and only suitable for palliative 
therapy.3 The predominant symptom of advanced 
esophageal cancer is dysphagia with 80–90% of all 
SDWLHQWVKDYLQJVRPHGLI¿FXOW\ LQVZDOORZLQJ1 It is 
one of the most distressing and debilitating symptoms 
in patients with cancer-related esophageal obstruction. 
Dysphagia leads to nutritional compromise, pain, and 
deterioration of quality of life.3 As the quality of life, 
and to some extent the quantity of life remaining to 
these patients depends to a large degree on their ability 
to swallow, the relief of dysphagia is therefore a priority 
for any palliative treatment of patients suffering from 
esophageal cancer.1,3
Several treatment modalities are used for 
the palliative care of dysphagia in patients with 
inoperable esophageal cancer, including radiotherapy 
(endoluminal and external-beam), endoscopic ablation 
(for example, by laser, cryotherapy, photodynamic 
therapy), endoluminal plastic and metallic stents, and 
resection or bypass surgery. Of those approaches, 
endoluminal stenting and radiation therapy are the 
ones most commonly used.4 
In the past there have been attempts to combine 
radiotherapy with stent placement in patients with 
esophageal cancer. These efforts are based on the 
premise that radiotherapy and stenting complement 
each other. Stents provide rapid relief of dysphagia and 
maintain nutrition during radiotherapy. Radiotherapy, 
in turn, provides lasting dysphagia relief by retarding 
tumor growth and, possibly, improves survival.1 
This paper was aimed to evaluate the comparison of 
palliative treatment using esophageal stenting alone or 
in combination with radiotherapy.
CLINICAL QUESTION
A 48 year-old man came with the chief complain of 
black stool since 2 days before admission. The history 
RIKLVGLVHDVHKDVVWDUWHGVLQFHD\HDUDJR$W¿UVWKH
VXGGHQO\KDGGLI¿FXOW\LQVZDOORZLQJIRRG3DLQLQWKH
throat or fever were denied. He was still able to eat solid 
food, but gradually he can only consume liquid food 
or just drink milk. This patient already went to other 
hospital and underwent esophagogastroduodenoscopy 
(EGD). The doctor said that there was a tumor in 
his esophagus, but the biopsy results were never 
conclusive although it has been done for seven times. 
The deployment of esophageal stent has been carried 
out in this patient at that time because there was already 
constricture at his esophagus. At 2 days before the 
DGPLVVLRQWKHSDWLHQWVWDUWHGWRSDVV¿UPEODFNVWRRO
three times a day in small quantities. It also became 
PRUHGLI¿FXOWIRUKLPWRVZDOORZIRRG7KHUHZDVORVV
of appetite but nausea and vomiting were denied. He 
also suffered from weight loss, approximately 10 kg in 
the last 3 months. Any other symptoms were denied. 
He has no history of chronic diseases such as diabetes 
mellitus, hypertension, heart disease, kidney disease, 
pulmonary disease, asthma, or allergies. He also did 
not admit for alcohol consumption or smoking. There 
is no history of similar disease or other chronic disease 
such as malignancy in the family. 
From a complete physical examination, stable 
hemodynamic was found. Abdominal examination 
showed palpable liver approximately 2 cm below 
processus xyphoideus. On rectal touché, black stool 
were found. No other abnormalities were found. From 
the laboratory examination at emergency ward, we 
found normocytic normochrome anemia (Hb 8.43 
PJG/0&9 À0&+ SJ DQG VOLJKWO\
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leukocytosis (Leu 10.600/uL). Electrolytes were 
normal (Sodium 137/Potassium 4.0/Chloride 104 
mEq/L) and also no elevation of transaminases (AST 
20/ALT 10 u/L) nor ureum/creatinine level (21.5/1.0 
mg/dL). Later on we also checked on the fecal occult 
blood test and the result was positive. Serologic 
markers for hepatitis B, C, and HIV infections 
showed negative result. The level of LDH was slightly 
increased (331 u/L) and AFP level was normal (0.9 
IU/mL). Hemostasis were normal with no prolonged 
PT nor aPTT. Chest X-Ray and electrocardiography 
showed no abnormalities. 
 Before the admission, this patient already 
underwent several examination at other hospital. Chest 
CT-scan showed esophagogastric tumor with stent 
deployed suspect malignancy and no abnormalities 
in the heart and lung. Esophagogastroduodenoscopy 
showed esophageal tumor with stent deployed and 
covered by tumor growth. The biopsy result showed 
reflux esophagitis with ulceration. OMD showed 
irregularity at gastroesophageal junction with stent 
deployed and narrowing lumen. Abdominal ultrasound 
VKRZHGGLVWDOHVRSKDJHDOWXPRULQ¿OWUDWHGWROHIWOREHV
of the liver. Abdominal CT-scan showed solid tumor 
at distal esophageal spread through cardia and fundus 
RI VWRPDFKQR LQ¿OWUDWLRQ WRDGMDFHQWYDVFXODU DQG
coeliacus truncus lymphadenopathy. 
Based on anamnesis, physical examination, 
laboratory and other supports, we conclude the list of 
problems in this patient are: (1) melena et cause GI 
bleeding dd/ tumor bleeding; (2) esophageal tumor et 
cause suspected malignancy with tumor bleeding and 
metastasis to the liver; (3) normocytic normochrome 
anemia et cause tumor bleeding dd/ anemia of chronic 
disorder. The patient was treated using the nasogastric 
tube to evaluate the bleeding and was started to be 
given liquid food 1700 kkal per day as soon as the 
bleeding stopped. Other treatment were intravenous 
Normal saline and Triofusin 500 mL, PPI 2 x 40 mg 
iv, Sucralfate 3x15 mL po, Vitamin K 3x10 mg iv, 
Transamin 3x500 mg iv, Lactulax 3x15 ml, Curcuma 
3x200 mg, and PRC transfusion with targeted Hb 10 
mg/dL.
During the treatment at our hospital, this patient 
underwent another EGD procedure and biopsy of the 
HVRSKDJXVWLVVXH+HZDVFRQ¿UPHGWRKDYHHVRSKDJHDO
squamous cell carcinoma spread to the stomach and 
also liver metastases. While deciding the next step of 
WUHDWPHQW WKH GLI¿FXOW\ RI VZDOORZLQJ IRRG LQ WKLV
patient is getting more serious. Sometimes he said that 
he is not even able to swallow liquid food. Apparently 
the use of esophageal stent may not be as effective as 
expected. 
Does a combination of esophageal stent and 
radiotherapy give the best outcome for the relief of 
dysphagia in patients with inoperable esophageal 
carcinoma compare to esophageal stenting alone?
METHOD
In order to answer the clinical question above, 
ZHQHHGWRVWDUWE\¿UVWV\VWHPDWLFDOO\FODULI\LQJWKH
question with PICO system, understanding what type 
of clinical question it is, and what type of study design 
is appropriate in searching the most relevant clinical 
evidence. By using PICO, a clinical question will have 
4 elements which are Patient/Problem, Intervention, 
Comparison, and Outcome. The following table shows 
PICO for our question:
Table 1. PICO model for the clinical question of this case
PICO Case
Patient/Problem Inoperable esophageal carcinoma
Intervention Esophageal stent
Comparison Esophageal stent combine with radiotherapy
Outcome Relief of dysphagia
We conduct a searching in PubMed site by using three 
keywords; they are “inoperable esophageal carcinoma” 
AND “esophageal stent” AND “radiotherapy” on June 
5th 2013. The searching detail is ((inoperable[All Fields] 
AND esophageal[All Fields] AND ("carcinoma"[MeSH 
Terms] OR "carcinoma"[All Fields])) AND 
(esophageal[All Fields] AND ("stents"[MeSH Terms] 
OR "stents"[All Fields] OR "stent"[All Fields]))) AND 
("radiotherapy"[Subheading] OR "radiotherapy"[All 
Fields] OR "radiotherapy"[MeSH Terms]). Based on 
this search strategy, we found 32 articles matched the 
keywords. From these 32 articles, only 10 articles were 
published in the last 5 years. Thus, from the searching 
step, there were 10 articles that go to the next process.
The next process was selection by reading all 
articles (10 articles). The articles which were included 
in this EBCR consist of study which compare 
combination of esophageal stent and radiotherapy 
directly with esophageal stent alone. There were 9 
articles excluded from analysis because it did not 
FRPSDUHWKRVHPRGDOLWLHVGLUHFWO\7KHIROORZLQJ¿JXUH
showed the selection process for the most relevant 
clinical evidence in this EBCR: 
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Figure 1. Selection process of articles for critical appraisal
We finally choose one randomized trial study 
written by Javed A, Pal S, Dash NR, Ahuja V, Mohanti 
BK, Vishnubhatla S, et al goes to the critical appraisal 
step. In appraising the scientific evidence of the 
article, we use the guidance of critical appraisal of a 
randomized controlled trial written by Guyatt et al in 
Critical Appraisal Skills Programme. Details of the 
article is described in the following table:
Table 2. Details of the article
Paper details
Authors Javed A, Pal S, Dash NR, Ahuja V, Mohanti BK, 
Vishnubhatla S, et al
Title Palliative Stenting With or Without Radiotherapy for 
Inoperable Esophageal Carcinoma: A Randomized 
Trial
Source J Gastrointest 2012;43:63-9
RESULTS
In this EBCR, one prospective, randomized study is 
collected and compares directly the duration of relief 
of dysphagia in patients with inoperable esophageal 
cancer treated with esophageal stenting alone (group 
I) or a combination of esophageal stenting and 
radiotherapy (group II), and to assess overall survival, 
treatment-related complications, and quality of life 
(QOL) of the patients. 
The result of this study showed that dysphagia 
VFRUHVLPSURYHGVLJQL¿FDQWO\LQ both groups following 
stent insertion. The scores were assessed at baseline 
(before the start of therapy), 1 week after esophageal 
stenting, 1 week after completion of radiotherapy (in 
group II), and every 2 months there after until death 
or until completion of the study. However, dysphagia 
relief was more sustained in group II than in group I (7 
vs. 3 months, p = 0.002). Overall median survival was 
VLJQL¿FDQWO\ higher in group II than in group I (180 vs. 
120 days, p = 0.009). Addition of radiotherapy following 
stenting prolonged the mean dysphagia-free survival 
(118.6 ± 55.8 vs. 96.8 ± 43.0 days, p = 0.054). Mean 
G\VSKDJLDIUHH VXUYLYDOZDVGH¿QHGDV VXUYLYDOZLWK
no or minimal dysphagia (dysphagia grade 0-1). There 
ZDVVLJQL¿FDQWLPSURYHPHQW in all QOL parameters at 
1 week after stenting. The QOL, KRZHYHUVLJQL¿FDQWO\
declined immediately after radiotherapy. There was 
no treatment-related mortality, and the incidence of 
complications was similar in the two groups.1
DISCUSSION
&DUFLQRPDRIWKHHVRSKDJXVLVGH¿QHGDVSULPDU\
cancer of the esophagus. About 10% of this cancer occur 
in the upper third of the esophagus (cervical esophagus), 
35% in the middle third, and 55% in the lower third. 
Squamous cell carcinoma and adenocarcinoma account 
for more than 90% of cases.1,5,6 A variety of causative 
factors have been implicated in the development of 
the disease. The etiology of squamous cell esophageal 
cancer is related to excess alcohol consumption and/
or cigarette smoking. The relative risk increases with 
the amount of tobacco smoked or alcohol consumed, 
with these factors acting synergistically.6 
Due to the lack of widespread screening methods, its 
insidious symptomatology, a late clinical presentation, 
and rapid progression, diagnosis is usually made 
at advanced stages.1,3 Progressive dysphagia and 
weight loss of short duration are the initial symptoms 
in the vast majority of patients. By the time these 
symptoms develop, the disease is usually incurable, 
VLQFH GLI¿FXOW\ LQ VZDOORZLQJ GRHV QRW occur until 
> 60% of the esophageal circumference is LQ¿OWUDWHG
with cancer.6 
Dysphagia LVGH¿QHGDVDVHQVDWLRQRI³VWLFNLQJ´
or obstruction of the passage of food through the 
mouth, pharynx, or esophagus. It may be associated 
with pain on swallowing (odynophagia), pain radiating 
to the chest and/or back, regurgitation or vomiting, 
and aspiration pneumonia.6 The obstruction of the 
esophagus by the tumor causes progres sive solid food 
dysphagia, often accompanied by weight loss. Weight 
loss > 10% body mass (at presentation) is an indepen-
dent indicator of a poor prognosis. This usually occurs 
once the esophageal lumen diameter is less than 13 
mm, which indicates advanced disease. The following 
table shows grades of dysphagia:7
Table 3. Grades of dysphagia
Grade Description
1 Normal swallowing
2 'LI¿FXOW\VZDOORZLQJVRPHKDUGVROLGVEXWFDQVZDOORZ
semisolids
3 Unable to swallow any solids but can swallow liquids
4 'LI¿FXOW\VZDOORZLQJOLTXLGV
5 Unable to swallow saliva
Dysphagia from inoperable esophageal cancer 
is a common and complex management problem, 
and there is no consensus on the ideal treatment 
approach.4 The stage of neoplastic disease, general 
patient condition and (in consequence) life expectancy, 
should be taken into ac count in choosing a method 
for palliative treatment of dyspha gia caused by 
esophageal cancer.8 Several treatment modalities are 
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Palliative Stenting With or Without Radiotherapy for Inoperable Esophageal Carcinoma
used for the palliative care of dysphagia in patients with 
inoperable esophageal cancer, including radiotherapy 
(endoluminal and external-beam), endoscopic ablation 
(for example, by laser, cryotherapy, photodynamic 
therapy), endoluminal plastic and metallic stents, and 
resection or bypass surgery.
Esophageal intubation for palliation has been used 
longer than 100 years. Symmonds in 1885 described 
WKH¿UVWVXFFHVVIXOLQWXEDWLRQXVLQJDPHWDOOLFGHYLFH
since then several types of endoprosthesis have been 
tried. Stenting has proved to be a convenient and long 
lasting method of palliation for malignant dysphagia. 
Use of covered self expandable metallic stents (SEMS) 
and more recently self expandable plastic stents (SEPS) 
has led to an increase in the success rate in palliative 
management of strictures of esophagus.8,9,10 
Since 1990, several case series, retrospective 
reviews, and prospective studies including more than 
2,000 patients have shown that self-expandable metal 
stents (SEMS) are effective in relieving dysphagia 
and improving dysphagia scores, with immediate 
success rates between 96% and 100%. SEMS provide a 
substantial progress in the management of patients with 
inoperable carcinoma esophagus. It is made up of an 
alloy, usually nitinol or stainless steel is deployed using 
HQGRVFRSLF DQGRUÀXRURVFRSLF WHFKQLTXHV TXLFNO\
restores oral intake and reduces hospital stay and cost.10 
However its use is limited by the cost, high rate of 
recurrent dysphagia, frequent need of re-interventions 
and several complications.1,4,8,9 
Complications associated with esophageal stents 
DUH JHQHUDOO\ FODVVL¿HG DV HLWKHU HDUO\ RU GHOD\HG 
Early complications occur immediately or within 2–4 
weeks postprocedure and include chest pain, fever, 
bleeding, gastroesophageal reflux disease, globus 
sensation, perforation, and stent migration. In one 
study, early complications were reported in up to 
32% of patients, with stent migration being the most 
common complaint. Delayed complications are more 
common than early ones and occur at least 2–4 weeks 
after placement of a stent. These complications include 
tumor ingrowth, stent migration, stent occlusion, 
GHYHORSPHQWRIHVRSKDJHDO¿VWXODHDQGUHFXUUHQFHRI
strictures. Delayed complications have been reported 
in 53–65% of patients, with a reintervention rate of up 
to 50%. Among both early and delayed complications, 
stent migration is the most common complication, 
occurring at a frequency of 7–75%.8,9 
Recurrent dysphagia was caused by tumor ingrowth 
(22%), bolus obstruction (21%), stent migration (9%), 
RUHVRSKDJHDO¿VWXODH8 This issue has led to the 
frequent need of re-intervention of the stent. Tumour 
ingrowth suggested that the longer the stent is in 
place the more tissue growth will be seen; hence, the 
longer time with the stent in situ, the more frequent the 
complications. APC was therefore the most frequent re-
intervention modality in our study. In some instances, 
placing a second stent could have been an option, but 
when the stented area is lengthened, the motility is 
also reduced. Stent dislocation was another frequent 
problem. Due to the problems with tumour/tissue 
ingrowth, covered stents are generally preferred, but it 
is also known that they tend to migrate more often. To 
avoid migration, the use of larger diameter stents seems 
tempting, but studies have shown that these may cause 
even more complications. The survival after SEMS 
placement was quite short (mean 116 days) which 
emphazises the need for quick relief of dysphagia 
rather than a more prolonged effect.11
Radiotherapy, on the other hand, provides effective 
and long-term relief of dysphagia. However, the onset 
of its effect is slow and required up to 6 weeks for 
PD[LPXPEHQH¿W%HVLGHVWKDWUDGLRWKHUDS\LQGXFHG
edema can actually worsen dysphagia during the early 
period. Stents placed before radiotherapy prevented 
this initial worsening of dysphagia. Patients who 
receive radiotherapy had a more sustained relief of 
dysphagia, which may have resulted from the inhibition 
of local tumor by radiotherapy, thereby delaying 
tumor overgrowth and ingrowth and keeping the stent 
patent for a longer duration. Besides the better relief of 
dysphagia, sustained improvement in nutritional status 
of patients who had received combination therapy 
might have also contributed to the improved survival 
in this group.1 
7KH VXUYLYDOEHQH¿WRI FRPELQHG LQWXEDWLRQDQG
UDGLRWKHUDS\ZDV ¿UVW VXJJHVWHG E\2JLOYLH HW DO
Since then, a few studies have reported superior results 
for stenting followed by radiotherapy with regard 
to both relief of dysphagia and survival in patients 
with inoperable esophageal cancer.1 A study by Yu 
et al showed that radiotherapy for esophageal cancer 
after esophageal stents placement is very helpful in 
treatment of advanced esophageal cancer. The stent 
inserted expanded the stenosis site and made it possible 
for brachytherapeutic treatment and radioactive 
source to pass easily and eventually dramatically 
prolonged the patients’ survival period.12 The dose of 
radiotherapy used in combination with stenting also 
need to be considered properly. Most studies have used 
radiotherapy in a dose range of 40–60 Gy. However, 
a higher dose of radiotherapy does not add to the 
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therapeutic value, and may increase the loco-regional 
toxicity.1
A few studies have reported a higher incidence of 
complications with radiotherapy after stent placement 
in esophageal cancer. In the present study, the overall 
rate of major complications was similar in the two 
treatment groups. This could be attributed to the use 
RI8OWUDÀH[VWHQWZKLFKH[HUWVWKHOHDVWUDGLDOIRUFH
insertion of stents before radiotherapy, adequate 
interval between the stent placement and radiotherapy, 
and lower dose of radiotherapy used.1 
Our patient underwent the deployment of esophageal 
stenting and showed several complications including 
bleeding and recurrent dysphagia which brought 
him to our hospital. From the anamnesis, we found 
out that the symptoms occurred few months after 
the stent deployment. We assumed that this patient 
suffered from delayed complication of esophageal 
stent caused by stent migration which shown from his 
imaging examination. The bleeding also occurred long 
time before he came to our hospital but never treated 
VXI¿FLHQWO\:HDVVXPHGWKLVZDVDUHVXOWIURPVWHQW
deployment or from the fragile and easily bleed tumor 
tissue. 
$W¿UVWZH GHFLGHG WR SODFH D QDVRJDVWULF WXEH
to relief the dysphagia and also given him medical 
therapy including vitamin K and transamin to stop the 
bleeding. It turned out that these treatment did not relief 
the dysphagia. We planned to do the re-intervention of 
the stent and combine it with radiotherapy to prolong 
the duration of dysphagia relief and improve overall 
survival for this patient. 
CONCLUSION
In this evidence-based case report (EBCR), we 
reported a man who suffered from dysphagia caused by 
inoperable esophageal carcinoma. Based on the critical 
appraisal of the randomized trial collected previously 
IURP3XE0HGZLWKVSHFL¿FFULWHULDVZHFRQFOXGHWKDW
a combination of esophageal stent and radiotherapy 
effectively prolongs duration of dysphagia relief and 
improves the overall survival, without increasing 
the incidence of complications. We planned to do 
the re-intervention of the stent and combine it with 
radiotherapy to prolong the duration of dysphagia relief 
and improve overall survival for this patient.
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